Head-To-Head Contrast: Femasys (NASDAQ:FEMY) and Pro-Dex (NASDAQ:PDEX)

Femasys (NASDAQ:FEMY) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Femasys and Pro-Dex”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$1.07 million	23.54	-$14.25 million	($0.81)	-1.36
Pro-Dex	$53.84 million	2.97	$2.13 million	$1.54	31.82

Pro-Dex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Femasys and Pro-Dex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-1,435.77%	-141.49%	-82.30%
Pro-Dex	9.17%	16.74%	9.98%

Insider & Institutional Ownership

65.3% of Femasys shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 12.3% of Femasys shares are owned by company insiders. Comparatively, 47.5% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Femasys has a beta of -2.83, suggesting that its stock price is 383% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Femasys and Pro-Dex, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	0	0	3	0	3.00
Pro-Dex	0	0	1	0	3.00

Femasys presently has a consensus price target of $10.00, indicating a potential upside of 809.09%. Pro-Dex has a consensus price target of $52.00, indicating a potential upside of 6.12%. Given Femasys’ higher probable upside, equities analysts plainly believe Femasys is more favorable than Pro-Dex.

Summary

Pro-Dex beats Femasys on 9 of the 13 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Pro-Dex

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.